Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$19.7 million.

  • Capricor Therapeutics' Free Cash Flow fell 6945.83% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$62.8 million, marking a year-over-year decrease of 6505.13%. This contributed to the annual value of -$41.2 million for FY2024, which is 5297.42% down from last year.
  • Per Capricor Therapeutics' latest filing, its Free Cash Flow stood at -$19.7 million for Q3 2025, which was down 6945.83% from -$20.4 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Free Cash Flow registered a high of $23.5 million during Q1 2022, and its lowest value of -$20.4 million during Q2 2025.
  • Its 5-year average for Free Cash Flow is -$6.9 million, with a median of -$7.3 million in 2025.
  • As far as peak fluctuations go, Capricor Therapeutics' Free Cash Flow surged by 79747.42% in 2022, and later tumbled by 29048.58% in 2025.
  • Over the past 5 years, Capricor Therapeutics' Free Cash Flow (Quarter) stood at -$6.0 million in 2021, then dropped by 26.68% to -$7.6 million in 2022, then tumbled by 59.99% to -$12.2 million in 2023, then dropped by 25.78% to -$15.3 million in 2024, then dropped by 29.18% to -$19.7 million in 2025.
  • Its Free Cash Flow stands at -$19.7 million for Q3 2025, versus -$20.4 million for Q2 2025 and -$7.3 million for Q1 2025.